American Century Companies’s CytomX Therapeutics CTMX Stock Holding History

American Century Companies’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$206K	Buy	+54,899	New	+$210K	﹤0.01%	2774
2020 Q1	–	Sell	-43,642	Closed	-$363K	–	1627
2019 Q4	$363K	Sell	43,642 -78,930	-64%	-$533K	﹤0.01%	1251
2019 Q3	$905K	Buy	+122,572	New	+$1.21M	﹤0.01%	1034
2018 Q4	–	Sell	-156,248	Closed	-$2.89M	–	1257
2018 Q3	$2.89M	Buy	156,248 +931	+0.6%	+$21.2K	﹤0.01%	963
2018 Q2	$3.55M	Sell	155,317 -49,743	-24%	-$1.27M	﹤0.01%	911
2018 Q1	$5.83M	Sell	205,060 -102,758	-33%	-$2.93M	0.01%	793
2017 Q4	$6.5M	Buy	307,818 +138,019	+81%	+$2.86M	0.01%	790
2017 Q3	$3.08M	Buy	169,799 +110,283	+185%	+$1.72M	﹤0.01%	959
2017 Q2	$922K	Buy	+59,516	New	+$897K	﹤0.01%	1151

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

American Century Companies's CTMX Position: Q2 2026 in Review

American Century Companies opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 54,899 shares worth $206K. The stake represents ﹤0.01% of the portfolio and ranks #2774 among its holdings. This is a return to the name: American Century Companies previously reported a position in CTMX as recently as Q4 2019.

American Century Companies first reported a position in CTMX in Q2 2017 and has held it in 9 quarters since. The position peaked at $6.5M in Q4 2017. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

American Century Companies held 54,899 shares of CytomX Therapeutics worth $206K as of Q2 2026.
CytomX Therapeutics was a new American Century Companies position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2774 holding.
American Century Companies first reported a position in CytomX Therapeutics in Q2 2017 and has held it in 9 quarters since.
American Century Companies's CytomX Therapeutics position peaked at $6.5M in Q4 2017.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.